SCF ENCYCLOPEDIA ENTRY

FAMILIAL ALZHEIMER’S DISEASE

SCF Registry Code: SCF-RDOS-NEURO-0003-FAD

Disease Classification: Monogenic Neurodegenerative Dementia

Parent Disease: ALZHEIMER’S DISEASE

Subtype Classification: Autosomal Dominant ALZHEIMER’S DISEASE (ADAD)

Domain: Neurogenetics • Neurodegeneration • Molecular Neurology • Neuroimmunology • Precision Medicine

I. Definition

FAMILIAL ALZHEIMER’S DISEASE (FAD) is a rare inherited form of ALZHEIMER’S DISEASE caused by pathogenic germline mutations that directly alter amyloid precursor protein processing and amyloid-beta production. The disease is typically inherited in an autosomal dominant pattern and is characterized by near-complete penetrance within affected families.

Within the SCF framework, FAD is classified as a Genetically Programmed Neurodegenerative Convergence Disorder, in which inherited molecular defects initiate a predictable cascade of proteostatic failure, neuroimmune activation, bioenergetic collapse, and progressive connectomic degeneration.

II. Epidemiology

III. Etiopathogenic Core

Primary Causative Genes

APP (Amyloid Precursor Protein)

Chromosome:

• 21q21

Pathogenic Effect:

• Increased amyloidogenic cleavage
• Elevated Aβ42 production
• Enhanced plaque formation

PSEN1 (Presenilin-1)

Chromosome:

• 14q24

Pathogenic Effect:

• Abnormal γ-secretase activity
• Excess Aβ42 generation

Clinical Characteristics:

• Most common cause of FAD
• Earliest onset forms
• Often aggressive progression

PSEN2 (Presenilin-2)

Chromosome:

• 1q42

Pathogenic Effect:

• Altered amyloid processing
• Increased amyloid deposition

Clinical Characteristics:

• More variable onset
• Variable penetrance

IV. SCF Fault Architecture

Using the SCF Pathophysiology Protocol, FAD exhibits a genetically initiated fault architecture that progresses through sequential system collapse.

V. Molecular Multi-Omics Pathogenesis Map

Genomics

Primary Drivers:

• APP
• PSEN1
• PSEN2

Outcome:

• Constitutive amyloidogenic signaling

Transcriptomics

Affected Pathways:

• Synaptic maintenance genes
• Inflammatory mediators
• Cellular stress response genes

Outcome:

• Progressive loss of neuronal adaptability

Epigenomics

Features:

• Accelerated epigenetic aging
• Neurodegenerative methylation signatures

Outcome:

• Disease amplification

Proteomics

Principal Abnormalities:

• Amyloid-beta accumulation
• Hyperphosphorylated tau
• Synaptic protein depletion

Outcome:

• Plaque and tangle pathology

Metabolomics

Abnormalities:

• ATP depletion
• Glucose hypometabolism
• Mitochondrial inefficiency

Outcome:

• Neuronal energy crisis

Interactomics

Affected Networks:

• PI3K/Akt
• mTOR
• MAPK
• NF-κB
• GSK3β

Outcome:

• Neurodegenerative signaling amplification

Connectomics

Affected Regions:

• Hippocampus
• Temporal cortex
• Posterior cingulate cortex
• Fronto-parietal networks

Outcome:

• Progressive cognitive decline

VI. Pathogenesis Flow (SCF Logic)

VII. Clinical Presentation

Early Manifestations

• Episodic memory impairment
• Executive dysfunction
• Language deficits
• Difficulty learning new information

Progressive Disease

• Cognitive decline
• Behavioral changes
• Functional impairment
• Visuospatial dysfunction

Advanced Disease

• Severe dementia
• Loss of independence
• Dysphagia
• Immobility

VIII. Diagnostic Framework

Clinical Criteria

Required Elements:

• Progressive cognitive decline
• Consistent neurological findings
• Positive family history

Genetic Confirmation

Pathogenic Variant Detection:

• APP
• PSEN1
• PSEN2

Gold Standard:

• Molecular genetic testing

Biomarkers

Cerebrospinal Fluid

• Reduced Aβ42
• Elevated total tau
• Elevated phospho-tau

Plasma

• pTau217
• pTau181
• Neurofilament Light Chain

Neuroimaging

MRI

Findings:

• Hippocampal atrophy
• Cortical volume loss

PET

Findings:

• Amyloid positivity
• Tau positivity
• FDG hypometabolism

IX. SCF Disease Tier Classification

X. Pathogens → Symptomatology → SCF Fault Tier Mapping

XI. SCF Therapeutic Mechanisms

SCF-PCR Preventative

Objectives:

• Delay molecular pathology
• Preserve mitochondrial function
• Reduce inflammatory priming

SCF-PCR Curative

Objectives:

• Reduce amyloid burden
• Modulate tau pathology
• Suppress neuroinflammation

SCF-PCR Restorative

Objectives:

• Restore synaptic integrity
• Enhance neuroplasticity
• Preserve network coherence

XII. PROJECT RHENOVA — Integration Pathways

Neurogenetic Axis

Primary Targets:

• APP
• PSEN1
• PSEN2

Neuroimmune Axis

Primary Targets:

• TREM2
• Microglial signaling
• Cytokine pathways

Neuroenergetic Axis

Primary Targets:

• ATP homeostasis
• Mitochondrial biogenesis
• Oxidative stress regulation

Connectomic Axis

Primary Targets:

• Synaptic preservation
• Neural network stability

Regenerative Axis

Primary Targets:

• Neuroplasticity
• Neurotrophic signaling

XIII. SCF Strategic Research Prioritization

XIV. Next Strategic Research Pathways

Pathway 1

APP mutation-specific therapeutic development.

Pathway 2

PSEN1 precision intervention programs.

Pathway 3

Gene-editing and gene-silencing technologies.

Pathway 4

Mutation-stratified clinical trial design.

Pathway 5

Pre-symptomatic prevention programs for mutation carriers.

Pathway 6

SCF multi-omic disease progression modeling.

Pathway 7

Integrated SCF therapeutic reconstruction utilizing targeted drug action, pharmacokinetic optimization, metabolic efficiency, resistance prevention, and safety-profile alignment.

SCF ENCYCLOPEDIA SUMMARY

FAMILIAL ALZHEIMER’S DISEASE is a rare autosomal dominant neurodegenerative disorder driven primarily by pathogenic mutations in APP, PSEN1, and PSEN2. Within the SCF framework, FAD represents a genetically programmed neurodegenerative convergence syndrome characterized by predictable progression from inherited proteostatic dysregulation to neuroimmune activation, mitochondrial failure, connectomic degeneration, and clinical dementia. Early identification of mutation carriers creates a unique opportunity for precision preventative intervention before irreversible neurodegeneration develops.

MASTER REGISTRY INDEX

SCF-RDOS-NEURO-0003-FAD — FAMILIAL ALZHEIMER’S DISEASE

SCF-ENC-FAD-0001 — SCF Encyclopedia Entry: FAMILIAL ALZHEIMER’S DISEASE

SCF-PATH-EXT-0001 — SCF Pathophysiology Protocol (Extended Version)

SCF-SCP-0001 — Synergistic Compatibility Principles

SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework

SCF-RHENOVA-FAD-0001 — FAMILIAL ALZHEIMER’S DISEASE Therapeutic Reconstruction Program

SCF-RDOS-NEURO-MASTER-0001 — Neuroscience Disease, Disorder & Condition Master Registry